LGR5-targeted CAR-T cell therapy - Carina Biotech
Alternative Names: LGR5 stem cell antigen - Carina BiotechLatest Information Update: 28 Aug 2026
At a glance
- Originator Carina Biotech
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Ovarian cancer
- No development reported Colorectal cancer; Haematological malignancies; Solid tumours
Most Recent Events
- 28 Aug 2026 No recent reports of development identified for preclinical development in Colorectal-cancer in Australia (Parenteral)
- 28 Aug 2026 No recent reports of development identified for preclinical development in Haematological-malignancies in Australia (Parenteral)
- 28 Aug 2025 No recent reports of development identified for preclinical development in Solid-tumours in Australia (Parenteral)